智通财经网·2025-12-09 11:49Core Insights - Fosun Pharma (02196) announced a licensing agreement with Pfizer on December 9, 2025, involving the oral small molecule GLP-1 receptor agonist (including YP05002) for exclusive global development, use, production, and commercialization rights [1][2] - The agreement includes an upfront payment of $150 million and potential milestone payments of up to $350 million based on clinical and commercialization progress [1] Group 1 - YP05002 is an independently developed oral small molecule GLP-1 receptor agonist with proprietary intellectual property, aimed at treating type 2 diabetes, obesity, and related diseases [2] - The mechanism of YP05002 includes promoting insulin secretion, reducing glucagon secretion, inhibiting gastric emptying, and suppressing appetite, which are beneficial for metabolic disorders [2] - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia [2] Group 2 - The licensing agreement reflects recognition of the company's innovative research and development capabilities by its partners [2] - This collaboration is expected to accelerate the clinical development and commercialization of the licensed product globally, potentially benefiting more patients worldwide [2]